RBC Capital Reaffirms Their Buy Rating on Bausch + Lomb Corporation (BLCO)

In a report released yesterday, Douglas Miehm from RBC Capital maintained a Buy rating on Bausch + Lomb Corporation, with a price target of $21.00. The company’s shares closed yesterday at $15.78.

Claim 30% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Miehm is a 4-star analyst with an average return of 4.4% and a 50.32% success rate. Miehm covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Bausch Health Companies, and Ligand Pharma.

Currently, the analyst consensus on Bausch + Lomb Corporation is a Hold with an average price target of $18.73.

Based on Bausch + Lomb Corporation’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.41 billion and a GAAP net loss of $58 million. In comparison, last year the company earned a revenue of $1.28 billion and had a GAAP net loss of $3 million

Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLCO in relation to earlier this year. Last month, Sam Eldessouky, the EVP & CFO of BLCO bought 4,000.00 shares for a total of $68,520.00.